Oncology Bytes: Dr. Nikhil Vasdev on TAR-200 & Bladder Preservation in High-Risk NMIBC | IUCS 2024

🗓️ Register for IUCS 2025: https://urologycancersummit.org/regis... 🎥 Oncology Bytes – IUCS 2024 | Featuring Dr. Nikhil Vasdev In this insightful episode, Dr. Nikhil Vasdev, Professor of Robotic Surgery and Consultant Urological Surgeon, provides an exclusive update from the SunRISe-5 clinical trial. This Phase 3, open-label, randomised study evaluates the innovative TAR-200 drug delivery system against traditional intravesical chemotherapy for patients with papillary-only high-risk non-muscle-invasive bladder cancer (NMIBC) recurring post-BCG therapy. 🔬 Key highlights include: Understanding the urgent need for effective treatments in recurrent papillary-only NMIBC The unique design of TAR-200 for sustained gemcitabine delivery Advantages of TAR-200 over standard chemotherapy (Mitomycin C, gemcitabine) Insights on patient eligibility, trial objectives, and ongoing recruitment Emphasis on bladder preservation strategies for elderly or surgery-ineligible patients 🌐 Learn more at: https://oncoassist.com/ --------------------------------------------------- 📲 Oncology at your fingertips. Download the ONCOassist app: 📥 iOS: https://apple.co/4iuMxfS 📥 Android: https://bit.ly/oncoassistonandroid 📥Webapp: https://bit.ly/ONCOassistOnWeb 🚀 SUBSCRIBE to the ONCOassist Youtube Channel for more expert insights! 🔔 Turn on notifications so you never miss an episode. 📌 FOLLOW US FOR UPDATES: 📍 LinkedIn: https://bit.ly/oncoassistlinkedin 📍 Twitter/X: https://bit.ly/oncoassisttwitter #IUCS2024 #OncologyBytes #NMIBC #BladderCancer #TAR200 #ClinicalTrials #BladderPreservation #UroOncology #CancerCare #Oncoassist #Oncoalert